Obesity drugs in clinical development
Autores: Halford JC
Revista
Curr Opin Investig Drugs
Año
2006
Citas
400
Type
Research Article
Subject
Human
Condition
Obesity / Lipid Metabolism
TL;DR
Review of anti-obesity drugs in clinical development including centrally-acting agents, peripheral satiety signal targets like GLP-1, and other weight loss mechanisms.
Abstract
A number of anti-obesity drugs are currently undergoing clinical development.. These include: (i) centrally-acting drugs, such as the noradrenergic and dopaminergic reuptake inhibitor radafaxine, the endocannabinoid antagonist rimonabant, the selective serotonin 5-HT2c agonist APD-356, and oleoyl-estrone; (ii) drugs that target peripheral episodic satiety signals, such as glucagon-like peptide-1.